Johns Hopkins Medicine is providing outpatient infusion therapy in Maryland for patients with COVID-19.
Johns Hopkins Medicine and the University of Maryland Medical System are operating an outpatient center located at the Baltimore Convention Center. The infusion center administers monoclonal antibody therapies authorized by the U.S. Food and Drug Administration (FDA) under an emergency use authorization (EUA). Referrals are required. Monoclonal antibody therapy helps prevent hospitalization or worsening of symptoms in certain patients with COVID-19, but it may not be appropriate for everyone.
Therapy consists of treatment with combination of casirivimab and imdevimab, administered simultaneously (known as Regeneron)
Monoclonal Antibody Therapy Locations
- The Baltimore Convention Center COVID-19 Infusion Center is open Tuesday, Wednesday, Thursday and Saturday from 1 - 4:30 p.m.
- Sibley Memorial Hospital, 5255 Loughboro Rd., N.W., Washington, DC 20016. Note: We are currently experiencing a high volume of infusion requests. Requests may only come from Sibley credentialed providers. Patients, please call your provider to inquire about monoclonal antibody therapy. Providers, please prescreen patients to ensure they meet eligibility criteria and call 202-537-4171 for schedule availability.
To refer a patient for treatment to the Baltimore Convention Center COVID-19 Infusion Center, outpatient providers should complete this Infusion Center online referral form.
The Baltimore Convention Center infusion suite team will review the referral form upon receipt and contact the patient to coordinate services as soon as possible.
The infusion combination therapy, casirivimab and imdevimab, has FDA EUA criteria, and has been demonstrated to reduce COVID-19 hospitalization or emergency room visits when administered within 10 days of symptom onset.
Therapy must be ordered for the treatment of mild to moderate COVID-19 in adults and pediatric patients who have positive results of direct SARS-CoV-2 viral testing, are 12 years of age or older, weigh at least 40 kilograms, and are at high risk for progressing to severe COVID-19 and/or hospitalization. High risk is defined as patients who meet at least one of the following criteria:
- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease/other chronic respiratory disease
- Are 12–17 years of age AND have a BMI ≥85th percentile for their age and gender based on CDC growth charts; OR sickle cell disease; OR congenital or acquired heart disease; OR neurodevelopmental disorders, such as cerebral palsy; OR a medical-related technological dependence, such as tracheostomy gastrostomy or positive pressure ventilation (not related to COVID-19); OR asthma, reactive airway disease or other chronic respiratory disease that requires daily medication for control
This therapy is not authorized for use in patients who:
- Are hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19
- Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity
The allocation methodology is based on duration of symptom onset (longest to be prioritized). There is no further risk stratification based on other clinical characteristics at this point. Which treatment is administered will be decided based on availability and logistics.
There is a chance that a patient’s clinical condition may change in the time between referral and arrival at the infusion center, and the patient may no longer be eligible for this treatment. We urge providers to discuss this with patients, and help manage their expectations.
Referring providers should reference the provider fact sheet:
*The infusion center at the Baltimore Convention Center is jointly operated by Johns Hopkins Medicine and University of Maryland Medical System. The University of Maryland Medical Center’s COVID-19 infusion center website is umms.org/InfusionCenter.
For Referring Providers - Sibley Memorial Hospital
Casivirimab-Imdevimab is currently being offered at this site. To refer a patient to Sibley, complete the requisition form and submit it to the Sibley Department of Pharmacy. Requests may only come from Sibley credentialed providers. Patients, please call your provider to inquire about monoclonal antibody therapy:
- By secure email to firstname.lastname@example.org (Note: Include [secure] in the subject line of the email to encrypt it to meet HIPAA requirement.)
- By fax to 202-537-0072. Please follow your fax with a phone call to the pharmacy department at 202-537-4171 to ensure prompt attention.
After receiving your requisition form, a pharmacy staff member will contact you/your office regarding approval or denial decisions based on drug availability and inclusion criteria. If the patient is a new Sibley patient, a medical record will be created. Appointments will be made on a first-come, first-served basis to ensure equitable and fair distribution. Once the order is placed, a Sibley staff member will contact the patient to coordinate services as soon as possible.